Evidence map›Paper›PMID 27659357›Full record

ArticleAnnals of the Royal College of Surgeons of England2017

Usefulness of chemoradiotherapy for inoperable gastric cancer.

T Taki, Y Hoya, A Watanabe, T Nakayoshi, T Okamoto, H Sekine, N Mitsumori, K Yanaga

Open access · bronzeAbstract read
In one paragraph

Article in Annals of the Royal College of Surgeons of England, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

T TakiDepartment of Surgery, Jikei University Daisan Hospital , Tokyo , Japan.
Y HoyaDepartment of Surgery, Jikei University Daisan Hospital , Tokyo , Japan.
A WatanabeDepartment of Surgery, Jikei University Daisan Hospital , Tokyo , Japan.
T NakayoshiDepartment of Surgery, Jikei University Daisan Hospital , Tokyo , Japan.
T OkamotoDepartment of Surgery, Jikei University Daisan Hospital , Tokyo , Japan.
H SekineDepartment of Radiology, Jikei University Daisan Hospital , Tokyo , Japan.
N MitsumoriDepartment of Radiology, Jikei University Daisan Hospital , Tokyo , Japan.
K YanagaDepartment of Surgery, Jikei University School of Medicine , Tokyo , Japan.
The Jikei University Hospital · JPJikei University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction Radiotherapy is not commonly used for the treatment of gastric cancer in Japan, where surgery is the standard local treatment. We report the results of chemoradiotherapy in patients with advanced or recurrent gastric cancer which was deemed difficult to treat surgically. Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed. Results The tumour response to chemoradiotherapy was categorised as complete, partial, stable or progressive in 5, 9, 3, and 4 patients, respectively, with an overall response rate of 67%. No serious complications such as gastrointestinal perforation or bleeding occurred, and no cardiac, hepatic or renal dysfunction developed during the follow-up period. The mean survival time was 19.8 months (range, 3-51 months). One patient died of another disease, 18 died of primary cancer and the cause of death was unknown in 2 patients. Conclusions Chemoradiotherapy appears to be an effective treatment for localised gastric cancer without distant metastases, but further studies are needed to determine the indications for chemoradiotherapy and late adverse effects, as well as the chemotherapy regimens to be used.

Indexed as

ChemoradiotherapyAdenocarcinomaAgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCisplatinDrug CombinationsFemaleFluorouracilHumansJapanMaleNeoplasm Recurrence, LocalOxonic AcidRadiotherapy, ConformalAntimetabolites, AntineoplasticCisplatinDrug CombinationsFluorouracilOxonic AcidS 1 (combination)TegafurAdvanced gastric cancerChemo-radiation therapyNon-curative resectionRecurrent gastric cancer

Identifiers

PMID27659357
PMCPMC5449671
OpenAlexW2522460161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.